GTCbio

Glenn D. Prestwich, Director of the Therapeutic Biomaterials Center, Special Presidential Assistant for Faculty Entrepreneurism and Presidential Professor of Medicinal Chemistry at University of Utah, will give a plenary keynote presentation on “Engineering a Clinical Biomaterial for Regenerative Medicine: From Bench to Business” at the 7th Modern Drug Discovery and Development Summit to be held...

David S. Goldstein, M.D. Ph.D., Senior Investigator and Chief of Clinical Neurocardiology at NINDS, NIH to give a keynote presentation titled “Willie Sutton’s Getaway Car and the Pathogenesis of Lewy Body Diseases” at GTC’s Advances in Neuropsychiatric Treatment Conference on Sept 22-23, 2011 in San Francisco, CA Dr. Goldstein has been at NIH since 1978, tenured in 1984 (NHLBI), and founded and...

Ray Miller, Global Business Development Manager in Biomaterials and Specialties, at DuPont Applied BioSciences, to give a presentation at GTC’s 2nd Annual Biobased Chemicals – Inception to Market Conference on July 7-8, 2011 in San Francisco, CA.

Elham Behshad, Ph.D., Principal Investigator at Incyte to give a presentation on a collaboration with Novartis titled “Phosphorylation State and Compound Selectivity; c-Met HTS as Case Study” at GTCbio’s 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA

Barbara Wirostko, Chief Medical Officer of Altheos will give a featured presentation at GTCbio’s 3rd Ocular Disease & Drug Discovery Conference, May 26-27, 2011 in Boston, MA.

Marcie Glicksman, Ph.D., Co-Director, Laboratory for Drug Discovery at Harvard Neurodiscovery Center to give presentation on “Protein Kinase Inhibitors for Neurodegenerative Diseases” at GTCbio’s 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA Dr. Glicksman will describe some of the challenges and promise of kinase inhibitors for neurodegenerative diseases. The...

William C. Shakespeare, Ph.D., Vice President, Drug Discovery at ARIAD Pharmaceuticals to give featured presentation on “Tackling Mutation-Based Resistance in Kinase Drug Discovery: Ponatinib, a Pan-BCR-ABL Inhibitor and AP26113, A Next Generation ALK Inhibitor” at GTCbio’s 6th Protein Kinases in Drug Discovery Conference on May 26-27, 2011 in Boston, MA Dr. Shakespeare will address how mutation...